Immune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programme
E.H. Baldini, Diana Giannarelli(Agostino Gemelli University Polyclinic), Valeria Stati(Istituti di Ricovero e Cura a Carattere Scientifico), Gianpiero Fasola, D. Turci(Azienda Ospedaliera San Camillo-Forlanini), Biagio Ricciuti(Harvard University), Giacomo Cartenì(Ospedale Antonio Cardarelli), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), Carmine Pinto(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Gianpiero Romano(Ospedale Vito Fazzi), Anna Illiano(University of Naples Federico II), Carmelo Tibaldi(Azienda Ospedaliero-Universitaria Careggi), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Francesco Verderame(Ospedale Vincenzo Cervello), Alessandro Lunghi(Rubber Research Institute), Luisa Fioretto(Ospedale SS. Annunziata), Enrico Cortesi(Sapienza University of Rome), Marina Chiara Garassino(University of Chicago), Vieri Scotti(University of Florence)
Cited by 1
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879